Background: Optimal graft versus host disease (GVHD) prophylaxis prevents severe manifestations without excess immunosuppression. Standard prophylaxis includes a calcineurin inhibitor (CNI) with low-dose methotrexate. However, single-agent CNI may be sufficient prophylaxis for a defined group of patients. Single-agent CNI has been used for GVHD prophylaxis for human leukocyte antigen (HLA)-matched sibling donor (MSD) bone marrow transplants (BMTs) in young patients at the Children's Hospital of Philadelphia for over 20 years. Here, we describe outcomes using this prophylactic strategy in a recent cohort.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with hematologic malignancies, bone marrow failure syndromes, primary immunodeficiencies, and Abbreviations: ATG, thymoglobulin; BMT, bone marrow transplant; CHOP, The Children's Hospital of Philadelphia; CI, confidence interval; CNI, calcineurin inhibitor; CSA, cyclosporine A; GVHD, graft versus host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; MSD, matched sibling donor; MTX, methotrexate; OR, odds ratio; sAA, severe aplastic anemia hemoglobinopathies. Graft versus host disease (GVHD) remains a significant cause of morbidity and mortality and occurs in as many as half of allogeneic HSCT recipients. 1 Currently, the most common pharmacologic prophylactic regimen to prevent GVHD is a calcineurin inhibitor (CNI), either cyclosporine A (CSA) or tacrolimus, in conjunction with methotrexate (MTX), administered as three or four doses in the first 2-weeks post-transplant. [2] [3] [4] This regimen is based on studies that demonstrated improved survival compared to those who received either agent alone. [5] [6] [7] [8] However, the inclusion of MTX as a second agent is associated with increased mucosal and hepatic toxicity, delayed engraftment, and increased infectious risk. 2, 5, 9 Moreover, when employing HSCT for the treatment of hematologic malignancies, several studies have demonstrated that acute GVHD is associated with a decreased risk of leukemic relapse, and has a positive impact on leukemia-free survival due to a graft-versus-leukemia effect. [10] [11] [12] Thus, in these cases, the ideal GVHD prophylactic regimen should effectively prevent severe GVHD while avoiding excess immunosuppression that might contribute to relapse or toxicity.
In general, pediatric patients have a lower incidence and decreased severity of GVHD than their adult counterparts and may warrant a less intensive approach to prophylaxis. 6, 13 There is early evidence to suggest that single-agent prophylaxis may be sufficient for the prevention of GVHD in patients undergoing transplantation for malignant indications and that less immunosuppression has a positive impact on event-free survival. 9, [14] [15] [16] [17] There are less data on the use of singleagent GVHD prophylaxis in patients undergoing HLA-matched sibling donor (MSD) HSCT for nonmalignant indications, particularly the use of single-agent tacrolimus. We hypothesized that GVHD prophylaxis with single-agent CNI would be safe and effective in pediatric patients undergoing MSD bone marrow transplant (BMT), particularly when both recipient and donor are young. This descriptive study contributes to the literature on the optimal pharmacologic GVHD prophylaxis in children.
METHODS

Study design
We identified a retrospective cohort of consecutive pediatric patients who underwent first MSD BMT for any indication between 2002 and 2014 at the Children's Hospital of Philadelphia (CHOP) and performed a manual review of their records. As per the institutional standards, since 2004 all patients less than 14 years with donors less than 14 years undergoing MSD BMT received a single-agent CNI for GVHD prophylaxis. The age determination was arbitrary, but based on the studies that showed higher risk of GVHD in older teens. [18] [19] [20] This study was approved by the CHOP Institutional Review Board with a waiver of informed consent.
Conditioning regimen
Conditioning regimen was chosen based on the best avail- A subset of patients received thymoglobulin (ATG) 3 mg/kg/day for 3 days to prevent graft rejection, including all patients with sAA, two patients with primary immunodeficiency, a single patient with hemoglobinopathy, and one patient with myelodysplastic syndrome.
Patients received steroid premedication with ATG infusions that completed 48 hr after ATG (prior to the start of transplant).
GVHD prophylaxis
As per institution standards, CSA or tacrolimus is administered as a continuous infusion from day −1 and patients are transitioned to an oral CNI twice daily once oral administration can be tolerated. In most cases, tacrolimus was the preferred oral CNI at CHOP due to its more favorable side effect profile with decreased hirsutism and gingival hyperplasia. Doses were adjusted to target through levels of 300-400 ng/ml for CSA and 5-10 ng/ml for tacrolimus. In patients with malignant disease without evidence of GVHD, the oral medication was 
Statistical analysis and study endpoint definitions
The following data were included for description and analysis: (i) demographic information, (ii) donor age and sex, (iii) transplant-related variables including indication for transplant and conditioning regimen, (iv) agents and duration of prophylaxis for GVHD, (v) development and maximum grade of GVHD, (vi) engraftment kinetics, (vii) relapse, and (viii) mortality and cause of death.
Acute GVHD was graded by standard clinical criteria and staged according to the Glucksberg criteria, and was collected as maximum documented grade prior to day +100 post-transplant. 21 Chronic GVHD was diagnosed and staged according to the Seattle clinical grading and staging system and was captured if documented anytime in 2 years post-transplant. 22 Biopsies were obtained when clinically indicated, but were not required for a patient to be determined to have acute or chronic GVHD.
Transplant-related mortality (TRM) was defined as any nonrelapse cause of death after BMT. Engraftment of neutrophils and platelets was defined as the first of three consecutive days with an absolute neutrophil count >0.5 × 10 9 /l and unsupported platelet count >20 × 10 9 /l. All statistical analyses were performed using Stata/1C (version 14. analyses; those who died or relapsed prior to 100 days post-transplant were excluded from chronic GVHD analyses.
RESULTS
Study population
The cohort comprised 52 children who underwent MSD BMT. No patient was lost to follow-up; all patients had data for 2 years post- 
GVHD prophylaxis
Most patients received intravenous CSA and transitioned to oral 
GVHD
The incidence of GVHD is shown in Table 2 . These rates were similar in a subanalysis by oral agent (Supplementary Table S2 ). Among patients who did not receive ATG as part of their conditioning, rates of acute GVHD were higher than in the cohort as a whole (29.7%), but rates of chronic GVHD were only 8.1% (Supplementary   Table S1 ). 
Hematopoietic recovery (Table 3)
Median times to engraftment were 18 days (IQR 14-22) for neu- 
Relapse and mortality
Two-year overall survival (OS) was 82.7% (95% CI: 69.4-90.6%, Figures 1C and 1D , respectively.
DISCUSSION
The primary objective of this retrospective study was to evaluate the efficacy of single-agent prophylaxis for prevention of GVHD in pediatric patients undergoing MSD BMT. Data from prospective randomized trials in adults have demonstrated that dual prophylaxis with CSA and MTX leads to lower incidence and decreased severity of GVHD than in those receiving CSA alone. 5, 23 However, these studies do not include pediatric patients. Because young age is associated with lower rates of GVHD, the optimal degree of immunosuppression to prevent GVHD while minimizing toxicity, risk of infection, and relapse rates in these lower risk patients is not fully understood. 6, 7, 18 Our data demonstrate that a CNI alone effectively prevents severe GVHD in this population: the overall incidence of grades 2-4 acute GVHD and chronic GVHD in this cohort were comparable to those reported in studies of children using dual prophylactic regimens. 2, 12, [24] [25] [26] [27] Results of the phase three randomized trial ASCT0431 demonstrate that among pediatric patients transplanted for acute leukemia, acute GVHD is significantly associated with improved event-free survival and a decreased rate of relapse. 12 In contrast, chronic GVHD is associated with significant morbidity and is the primary factor associated with poor quality of life post-transplant. 28, 29 Therefore, for patients with malignant conditions, the goal of a GVHD prophylactic strategy is to prevent extensive chronic GVHD but allows for mild to moderate acute and chronic GVHD. 30, 31 A few studies have used single-agent prophylaxis in pediatric patients with a malignant indication for transplant to maximize a graft-versus-leukemia effect. The Children's Cancer Group study 2891 leveraged a single-agent strategy in 150 children with acute myeloid leukemia undergoing MSD BMT. Using single-agent MTX as prophylaxis, they found overall low rates of severe acute GVHD, especially in children younger than 10 years in whom the rate of grades 3-4 acute GVHD was only 4.6%. However, the rate of chronic GVHD was 21.3%. 31 prophylaxis (85% vs. 42%). 17 In the current study, which included 35 children with malignant indications for transplantation, the rate of grades 2-4 acute GVHD (32.4%)
is acceptable given the very low rates of grades 3-4 acute GVHD and chronic GVHD (8.8% and 9.1%, respectively). The low rate of relapse in patients with malignancy may be partially attributable to the rate of grades 1-2 acute GVHD observed in these patients (44.2%). These results contribute to this new body of data suggesting that single-agent prophylaxis with a CNI is adequate for the prevention of severe GVHD in young children and donors and may improve relapse-free survival.
Among those with nonmalignant indications for transplant, who do not stand to benefit from the graft-versus-leukemia effect, rates of GVHD were lower than those transplanted for malignancy. Age and frequency of sex concordance between recipient and donor were similar between malignant and nonmalignant patients, however nonmalignant patients received prophylactic immunosuppression for a longer duration. In addition, the majority of the nonmalignant patients received lymphodepleting serotherapy with ATG as part of conditioning to facilitate engraftment. The inclusion of this agent contributed to the lower rates of GVHD in the patients without malignancy. 24, 32, 33 In the subset of patients with sAA, no patient (0/11) developed GVHD. Moreover, among this cohort, no patient died or experienced graft failure. Reported rates of GVHD in sAA range from 0% to 60%
and utilize a variety of multiagent GVHD prophylactic strategies. [34] [35] [36] [37] A single prospective study has compared single-agent CNI to combination therapy with MTX in both adults and children with aplastic anemia and found similar rates of acute GVHD in the two groups (30% vs. 38%). 38 Compared to this study, the sAA patients in our cohort had a lower median age (8 years compared to 18 years) and received ATG, both of which may account for the much lower rates of GVHD that we found. Though the sample size is small, the results described here suggest that more study is warranted, and less immunosuppression may suffice to facilitate engraftment and prevent GVHD in children with sAA.
There are no published data on the use of single-agent prophylaxis in patients with primary immunodeficiencies, hemoglobinopathies, or hemophagocytic lymphohistiocytosis; however, there were so few patients transplanted for these indications in our cohort that we are unable to generalize our results beyond reporting that this approach was used in this small group.
In contrast to the previously performed analyses of monotherapy in either malignant or nonmalignant cohorts, the majority of the patients in this cohort transitioned to oral tacrolimus upon discharge.
This macrolide immunosuppressant, which has a mechanism of action similar to that of cyclosporine, effectively prevents GVHD but has a more favorable side effect profile including less hirsuitism and gingival hyperplasia, and better oral tolerability. 39 Since its introduction, tacrolimus has been used in combination therapy for the prevention of GVHD in both malignant and nonmalignant populations. 24, 35, 40, 41 The data presented here demonstrate rates of GVHD with tacrolimus monotherapy are comparable to prophylactic regimens that include CSA. More research is needed to understand the best agent and dosing regimen for single-agent therapy.
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